Anthill, a digital communications agency focused on the life science industry, is expanding its services for local clients based in Germany, Austria and Switzerland.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.